To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Ewing sarcoma treatment: assessment of cyclophosphamide and etoposide on survival rates

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
August 2013

Ewing sarcoma treatment: assessment of cyclophosphamide and etoposide on survival rates

Vol: 2| Issue: 7| Number:614| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients-

J Clin Oncol. 2008 Sep 20;26(27):4385-93. doi: 10.1200/JCO.2008.16.5720

Contributing Authors:
M Paulussen AW Craft I Lewis A Hackshaw C Douglas J Dunst A Schuck W Winkelmann G Köhler C Poremba A Zoubek R Ladenstein H van den Berg A Hunold A Cassoni D Spooner R Grimer J Whelan A McTiernan H Jürgens European Intergroup Cooperativ

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

647 patients with localized Ewing sarcoma were sorted into two risk groups based on the stage and tumour volume. Patients were allocated to the standard-risk (SR) group if their localized tumours were less than 100 mL in volume. Patients with localized tumours greater than 100 mL or with metastatic disease were allocated to the high-risk (HR) group. The 155 SR patients were then randomized to rece...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue